Phase III NODE-301 trial evaluating etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT) fails to meet primary outcome

RCT (n=431) showed etripamil, a short-acting calcium channel blocker, did not achieve primary endpoint of time to conversion of SVT to sinus rhythm vs placebo over 5 hour period following drug administration (median time: 25 minutes etripamil vs. 50 minutes placebo, p=0.12).


Biospace Inc.